Topical JAK inhibitors FDA approved ruxolitinib 1 5 crm for short term and noncontinuous chronic tx in pts 12 yo w mild to moderate AD don t exceed 20 of BSA or apply 60 g wk black box warnings include serious infxns mortality malignancies e g lymphoma MA

<b>Topical JAK inhibitors:</b> FDA approved ruxolitinib 1.5% crm for short-term and noncontinuous chronic tx in pts ≥12 yo w/ mild to moderate AD (don’t exceed 20% of BSA or apply >60 g/wk); black box warnings include serious infxns, mortality, malignancies (e.g., lymphoma), MACE, and thrombosis.² AAAAI/ACAAI suggests <i>against</i> adding topical JAK inhibitors for mild to moderate AD refractory to moisturization alone.¹